详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Immunosuppressive cells in oncolytic virotherapy for glioma: challenges and solutions

82| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Harvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. [2]Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

出处：

DOI：

ISSN：

关键词： oncolytic virus glioma immunosuppressive glioblastoma macrophages microglia MDSCs tumor microenvironment

摘要：

Glioblastoma is a highly aggressive form of brain cancer characterized by the abundance of myeloid lineage cells in the tumor microenvironment. Tumor-associated macrophages and microglia (TAM) and myeloid-derived suppressor cells (MDSCs), play a pivotal role in promoting immune suppression and tumor progression. Oncolytic viruses (OVs) are self-amplifying cytotoxic agents that can stimulate local anti-tumor immune responses and have the potential to suppress immunosuppressive myeloid cells and recruit tumor-infiltrating T lymphocytes (TILs) to the tumor site, leading to an adaptive immune response against tumors. However, the impact of OV therapy on the tumor-resident myeloid population and the subsequent immune responses are not yet fully understood. This review provides an overview of how TAM and MDSC respond to different types of OVs, and combination therapeutics that target the myeloid population to promote anti-tumor immune responses in the glioma microenvironment.Copyright © 2023 Liu, Piranlioglu, Ye, Shu, Lei and Nakashima.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区医学

小类 | 2 区微生物学 2 区免疫学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区免疫学 2 区微生物学

JCR分区：

出版当年[2021]版：

Q1 MICROBIOLOGY Q2 IMMUNOLOGY

最新[2023]版：

Q1 MICROBIOLOGY Q2 IMMUNOLOGY

影响因子： 4.6 最新[2023版] 5.1 最新五年平均 6.073 出版当年[2021版] 6.34 出版当年五年平均 5.293 出版前一年[2020版] 5.7 出版后一年[2022版]

第一作者：

第一作者单位： [1]Harvey Cushing Neuro-Oncology Laboratories, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. [2]Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment [2]Glioma-derived LRIG3 interacts with NETO2 in tumor-associated macrophages to modulate microenvironment and suppress tumor growth [3]Targeting UDP-α-D-glucose 6-dehydrogenase alters the CNS tumor immune microenvironment and inhibits glioblastoma growth [4]Targeting UDP-alpha-D-glucose 6-dehydrogenase alters the CNS tumor immune microenvironment and inhibits glioblastoma growth [5]Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis [6]LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization [7]The GBM Tumor Microenvironment as a Modulator of Therapy Response: ADAM8 Causes Tumor Infiltration of Tams through HB-EGF/EGFR-Mediated CCL2 Expression and Overcomes TMZ Chemosensitization in Glioblastoma [8]Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment [9]Trem2 promotes glioma progression and angiogenesis mediated by microglia/brain macrophages [10]Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling